Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical
The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical. The post Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical appeared first on GEN - Genetic…
Boehringer Ingelheim and Sino Biopharmaceutical (SBP Group) have entered a multi-program, up-to-$7.4 billion-plus collaboration to develop novel cancer therapies. The strategic agreement combines the companies' expertise in antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies to expand their oncology portfolio. SBP Group, through its wholly-owned subsidiary LaNova Medicines, will lead early development of five preclinical programs, while Boehringer Ingelheim may later exercise options for exclusive development, manufacturing, and commercialization rights for four of those programs outside China, Hong Kong, and Macau.
The remaining two programs will have worldwide rights. Upfront and near-term payments total $358 million, with up to $7 billion in tiered royalties tied to option-exercise, development, regulatory, and commercial milestones. The collaboration aligns with Boehringer Ingelheim's commitment to building a broad and differentiated oncology portfolio, including cancer cell-directed and immuno-oncology therapies.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
